CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 238 target
Drug / intervention
Donepezil Hydrochloride +1 moredrug
Likely dose
Donepezil Hydrochloride 5 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03907371
NCT03907371Phase 2Unknown
CompareCT.gov

The Effect of Donepezil in Radiotherapy-related Cognitive Impairment: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University·interventional·Posted Apr 9, 2019·Updated Nov 25, 2019

In Brief

A Phase 2 clinical trial evaluating Donepezil Hydrochloride and Placebo for Radiation Injuries and Cognitive Impairment. Targeting 238 participants across 1 site.

Detailed Summary

Purpose: This randomized, double-blind, placebo-controlled clinical trial aims to evaluate the therapeutic effects of donepezil in radiotherapy-related cognitive impairment. Further study details as provided by Sun Yat-sen Memorial Hospital, Sun Yat-sen University / Yameitang. Primary outcome measure: cognitive improvement, which is determined by the difference value of ADAS-cog score before and after the treatment of donepezil.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation Injuries, Cognitive Impairment
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
2020202120222023202420252026
First PostedApr 9, 2019
Enrollment StartMay 1, 2019
Primary CompletionDec 31, 2022
TodayJul 1, 2026
Enrollment to primary: 3.7 yearsPosted 7.2 years ago

Interventions

Donepezil Hydrochloridedrug

Donepezil will be used with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24).

Placeboother

Placebo will be used with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24).